Company News

Company News

English

Polaris Group Announces its listing on the Taiwan Stock Exchange on June 6, 2022

TAIPEI, Taiwan and SAN DIEGO, Calif., June 6, 2022 – Polaris Group (“Polaris”) (TWSE: 6550), a multinational biopharmaceutical company focused on research and development of novel biological drugs for cancer and other metabolic diseases

Read More
English

Polris Group received approval from the Listing Review Committee of Taiwan Stock Exchange for Primary Listing

The Taiwan Stock Exchange Corporation held its 755th Listing Review Committee meeting on March 4, 2022 and approved the application of Polaris Group for primary …

Read More
English

Polaris Pharmaceuticals steps into mRNA technology and actively integrates macromolecular pharmaceutical technology

Multinational biotech company Polaris signed an industry sponsored research agreement with UC Irvine’s (UCI) Vaccine Research and Development Center to fund “Fluvid,” a universal messenger RNA (mRNA) influenza and …

Read More
English

Polaris Pharmaceuticals applies for the first listing

Polaris Group Polaris Pharmaceuticals – KY (6550TW) rush to the stock exchange to apply for the first listing of shares before the end of 2021! …

Read More
Scroll to Top